Bliss GVS Pharma Ltd NSE:BLISSGVS:
BLISS GVS PHARMA JUNE-QUARTER CONSOL NET PROFIT 430.4 MILLION RUPEES
BLISS GVS PHARMA JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 2.07 BILLION RUPEES
Bliss GVS Pharma June-Quarter Consol Net Profit 430.4 Million Rupees
Bliss GVS Pharma Limited on 6ix
Story so far
Earlier from Bliss GVS Pharma
- Bliss GVS Pharma Gets Show Cause From Tax Department Over Recovery Of Refund Of 66.4 Million Rupees
- BLISSGVS: Revenue up, net profit down; subsidiary sale and dividend declared, restructuring ahead
- BLISSGVS: Quarterly revenue and profit grew modestly, with stable performance in core pharma operations
- BLISSGVS: Revenue and net profit increased, with new leadership and regulatory fine payment noted
- BLISSGVS: Q1 FY25 saw year-over-year growth in revenue and profit, with improved margins and ESOP activity
Later from Bliss GVS Pharma
- BLISSGVS: Strong Q1 FY26 growth in revenue and profit, with key subsidiary divestment completed
- Bliss GVS Pharma Ltd - Appoints Narsimha Shibroor Kamath As CEO
- Bliss Gvs Pharma Receives Tax Demand Of 166.9 Million Rupees From Tax Department
- Bliss GVS Pharma Sept-Quarter Consol Net Profit 272.5 Million Rupees
- Bliss GVS Pharma Incorporates Theralife Pharma In Kenya
Follow Bliss GVS Pharma into a list and get an email when it puts out news.
Follow Bliss GVS Pharma